1 completed, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow RAD1901: new trials by email Literature Review of RAD1901 trials Research Report on RAD1901
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Elacestrant, Standard of Care - Breast Cancer | Phase 3 | Completed | Stemline Therapeutics, Inc. | 478 | 2019-05-10 | 2025-09-15 |
Breast Neoplasms (1)
MedSIR (1) · Stemline Therapeutics, Inc. (1)
Austria (2) · France (2) · Greece (2) · Italy (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1)
Antonio Llombart-Cussac, M.D., Ph.D. (1)